| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Moracin C does not have a single well-defined molecular target. It exhibits multiple biological activities, including antibacterial activity through inhibition of FabI (enoyl-ACP reductase) and fatty acid synthesis. It also shows anti-inflammatory activity by inhibiting the production of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and suppressing nitric oxide (NO) release and LPS-activated reactive oxygen species (ROS) in cells.
|
|---|---|
| ln Vitro |
The release of LPS-activated reactive oxygen species (ROS) and nitric oxide (NO) from RAW264.7 cells is inhibited by moracin C (1-50 μM, 24 hours) [1]. Moracin C inhibits RAW264 at 1–50 μM for 2 hours. Pro-inflammatory cytokines (IL-1β, IL-6, and TNF) in LPS-activated RAW 264.7 cells 7 cells The mRNA and protein expression of iNOS and COX-2 are inhibited by moracin C (1-50 μM, 2 h) [1]. The phosphorylation of p38, ERK, and JNK in LPS-activated RAW 264.7 cells is inhibited by moracin C (1-50 μM, 2 hours) [1]. Creation of
In vitro, Moracin C exhibits potent and broad-spectrum antibacterial activity against Gram-positive bacteria through inhibition of FabI and fatty acid synthesis. It also shows anti-inflammatory activity by inhibiting nitric oxide (NO) release and LPS-activated reactive oxygen species (ROS) in cells. Moracin C inhibits the production of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α. These activities make it a valuable tool for studying antibacterial and anti-inflammatory mechanisms. |
| ln Vivo |
Moracin C (100 mg/kg, gavage, mice) is rapidly and well absorbed within the body, and is widely distributed in the gastrointestinal tract, liver, kidneys and liver [2].
In vivo activity of Moracin C has not been extensively reported. As a phytoalexin with antifungal and antibacterial properties, it plays a role in plant defense. Its anti-inflammatory activities suggest potential for treating inflammatory conditions, but detailed in vivo efficacy data are limited in publicly available sources. |
| Enzyme Assay |
The in vitro enzyme assay for Moracin C typically involves measuring its inhibition of FabI (enoyl-ACP reductase) activity. Recombinant FabI is incubated with the compound at various concentrations in the presence of NADH and crotonyl-CoA or other substrates. Enzyme activity is measured by monitoring the decrease in NADH absorbance at 340 nm. Antibacterial activity can be assessed using broth microdilution assays to determine minimum inhibitory concentrations (MICs) against Gram-positive bacteria.
|
| Cell Assay |
RT-PCR[1]
Cell Types: RAW -α)[1]. 264.7 Macrophage Tested Concentrations: 1, 10, 25, 50 μM Incubation Duration: 2 hrs (hours) Experimental Results: Inhibited LPS-induced iNOS and COX-2 mRNA expression. Western Blot Analysis[1] Cell Types: RAW 264.7 Macrophage Tested Concentrations: 1, 10, 25, 50 μM Incubation Duration: 2 h Experimental Results: Inhibited LPS-induced TLR4 expression and NF-κB activation. Levels of phosphorylated p38, ERK and JNK were diminished. The in vitro cell-based assay for Moracin C involves culturing macrophages or other immune cells and treating them with the compound to assess effects on inflammatory responses. Cells are stimulated with LPS in the presence or absence of Moracin C at various concentrations. Nitric oxide (NO) production is measured using the Griess assay. Reactive oxygen species (ROS) levels are measured using fluorescent probes such as DCFH-DA. Cytokine production (IL-1β, IL-6, TNF-α) is measured by ELISA. Cell viability is assessed using MTT or CellTiter-Glo assays. |
| Animal Protocol |
Animal/Disease Models: Mouse (PK Assay) [2]
Doses: 100 mg/kg Route of Administration: po (oral gavage) Experimental Results: pharmacokinetic/PK/PK characteristics of Moracin C. Parameters Terminal half-life (min) Cmax (μg/mL) Tmax (min) CLR (mL/min/kg) 100 mg/kg 256 1.79 15 0.032 In vivo animal studies for Moracin C have not been extensively reported. If conducted, such studies might involve mouse models of inflammation or bacterial infection. Moracin C would be administered orally or intraperitoneally, and inflammatory markers, bacterial load, and clinical signs would be assessed. Standard protocols for inflammation or infection models would be employed. No specific data are available. |
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Moracin C have not been extensively characterized. As a small molecule with a molecular weight of 310.34 and a molecular formula of C19H18O4, it is expected to have moderate oral bioavailability. The compound is a natural product with multiple hydroxyl groups, suggesting it may undergo glucuronidation and sulfation metabolism. Detailed PK parameters are not available from publicly accessible sources.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Moracin C has not been systematically evaluated. As a natural product with antibacterial and anti-inflammatory activities, it may have a favorable safety profile, but this has not been confirmed in controlled toxicology studies. Standard toxicology assessments would include acute and sub-chronic toxicity studies in rodents, with endpoints including clinical signs, body weight, clinical pathology, and histopathology. No specific toxicity data are available.
|
| References | |
| Additional Infomation |
Moracin C belongs to the benzofuran class of compounds. It has been reported to exist in mulberry trees (Morus cathayana), wicker mulberry (Morus wittiorum), and other organisms with relevant data.
Moracin C is a naturally occurring phytoalexin and research compound, not approved for clinical use. It is found in diseased mulberry and exhibits antifungal, antibacterial (via FabI inhibition), and anti-inflammatory activities (inhibiting NO, ROS, and pro-inflammatory cytokines). Moracin C is a valuable tool for studying antibacterial mechanisms, fatty acid synthesis, and inflammatory responses. |
| Molecular Formula |
C19H18O4
|
|---|---|
| Molecular Weight |
310.349
|
| Exact Mass |
310.12
|
| Elemental Analysis |
C, 73.53; H, 5.85; O, 20.62
|
| CAS # |
69120-06-5
|
| PubChem CID |
155248
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
439.4±35.0 °C at 760 mmHg
|
| Melting Point |
198 - 199 °C
|
| Flash Point |
219.6±25.9 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.664
|
| LogP |
4.46
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
23
|
| Complexity |
419
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ZTGHWUWBQNCCOH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H18O4/c1-11(2)3-6-15-16(21)7-13(8-17(15)22)18-9-12-4-5-14(20)10-19(12)23-18/h3-5,7-10,20-22H,6H2,1-2H3
|
| Chemical Name |
1,3-Benzenediol, 5-(6-hydroxy-2-benzofuranyl)-2-(3-methyl-2-buten-1-yl)-
|
| Synonyms |
Moracin C;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~805.57 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.70 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2222 mL | 16.1108 mL | 32.2217 mL | |
| 5 mM | 0.6444 mL | 3.2222 mL | 6.4443 mL | |
| 10 mM | 0.3222 mL | 1.6111 mL | 3.2222 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
